JP4627263B2 - ラクトフェリン・ポリペプチド及びその製造方法 - Google Patents
ラクトフェリン・ポリペプチド及びその製造方法 Download PDFInfo
- Publication number
- JP4627263B2 JP4627263B2 JP2005515538A JP2005515538A JP4627263B2 JP 4627263 B2 JP4627263 B2 JP 4627263B2 JP 2005515538 A JP2005515538 A JP 2005515538A JP 2005515538 A JP2005515538 A JP 2005515538A JP 4627263 B2 JP4627263 B2 JP 4627263B2
- Authority
- JP
- Japan
- Prior art keywords
- lactoferrin
- amino acid
- inflammatory
- elastase
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 44
- 102000010445 Lactoferrin Human genes 0.000 title description 50
- 108010063045 Lactoferrin Proteins 0.000 title description 50
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 title description 47
- 229940078795 lactoferrin Drugs 0.000 title description 47
- 235000021242 lactoferrin Nutrition 0.000 title description 47
- 102000004196 processed proteins & peptides Human genes 0.000 title description 28
- 229920001184 polypeptide Polymers 0.000 title description 25
- 238000004519 manufacturing process Methods 0.000 title description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 20
- 108010067372 Pancreatic elastase Proteins 0.000 description 20
- 150000001413 amino acids Chemical group 0.000 description 19
- 230000002757 inflammatory effect Effects 0.000 description 18
- 230000001939 inductive effect Effects 0.000 description 14
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 13
- 102000050459 human LTF Human genes 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 208000027866 inflammatory disease Diseases 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 108010062580 Concanavalin A Proteins 0.000 description 8
- 102000019034 Chemokines Human genes 0.000 description 6
- 108010012236 Chemokines Proteins 0.000 description 6
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 5
- 238000000760 immunoelectrophoresis Methods 0.000 description 5
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 229940072440 bovine lactoferrin Drugs 0.000 description 4
- 230000014564 chemokine production Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 208000031462 Bovine Mastitis Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000009704 beneficial physiological effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- OQTDZEJJWWAGJT-KKUMJFAQSA-N Phe-Lys-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O OQTDZEJJWWAGJT-KKUMJFAQSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000021995 interleukin-8 production Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000023185 monocyte chemotactic protein-1 production Effects 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
「Ala−Pro−Arg−Lys−Asn−Val−Arg−Trp−Cys−Thr−Ile−Ser−Gln−Pro−Asp−Ser−Phe−Lys」のアミノ酸配列で表されるアミノ酸配列からなるペプチドである。
また、特許文献2には、ウシ・ラクトフェリンを、プロテアーゼにより酵素分解し、酵素分解物から上記ペプチドを採取する技術が記載されている。
エラスターゼは、炎症時には補体成分やグロブリンを分解することが知られている(Am.J.Pathol.1979.94.75−83.,Elastase.(R.P.Mecham,ed)1986.Catalytic and biological properties.In:Biological of Extracelluler Matrix Orlando,FL:Academic Pess,217−320.,Biochemistry.1997.16.3390−3396.)。
しかしながら、このエラスターゼとラクトフェリンの関与を報告した事例はない。また、細菌性疾患で、細菌の産生する酵素により分解されるラクトフェリンについても、その生理作用は報告されていない。
本発明では、炎症性疾患で増加するエラスターゼに着目し、ラクトフェリンが分解されることを明らかとし、分解されたラクトフェリン中に各種炎症性サイトカインやケモカインの産生誘導活性を有するポリペプチドを分離できるようにしたものである。
また、このポリペプチドより、ヒトのラクトフェリンに存在するアミノ酸配列を有するポリペプチドを合成し、この様な炎症誘起活性を有する新規ラクトフェリン・ポリペプチドを見出した。本発明はこの新知見に基づき発明したものである。
本発明の各種ケモカイン産生誘導活性物質は、上述の小分子ラクトフェリン又上述のペプチドのいずれか1つからなることを特徴とする。
本発明のNFκBの発現増強物質は、上述の小分子ラクトフェリン又上述のペプチドのいずれか1つからなることを特徴とする。
前記アミノ酸配列はFKDCHLA又はGQKDLLFKDSAIであることを特徴とする。
そして、炎症性疾患の検体から得られたラクトフェリンと、エラスターゼ処理したラクトフェリンを、コンカナバリンA(Con A)二次元免疫電気泳動法によりその泳動像を観察した。
泳動後、PVDF膜(BioRad,USA)に転写し、各検体に共通して認められたバンドを切り出した後、N−末端アミノ酸配列をアミノ酸シークエンサー(Hewlett Packard,USA)により解析した。
そして、各ラクトフェリン・ポリペプチドを作成し、サイトカインならびにケモカインの産生誘導能を各種細胞により解析し、炎症誘起活性を有するペプチドを確定した。
本願発明におけるアミノ酸配列は、Phe−Lys−Asp(略記号:FKD)を含むペプチドである。また、N−アミノ酸配列の位置もC末領域に近い部分に位置している。
そのため、このFKDを含むラクトフェリン・ポリペプチドが炎症誘起作用を示すものである。
これより下流に位置する他の二つのドメインは未報告のものであった。第3図に示す。
Claims (1)
- GQKDLLFKDSAIで表されるアミノ酸配列からなるペプチド 。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2004/001614 WO2005049650A1 (ja) | 2004-02-16 | 2004-02-16 | ラクトフェリン・ポリペプチド及びその製造法並びに炎症誘起物質 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010199281A Division JP2011006468A (ja) | 2010-09-06 | 2010-09-06 | ラクトフェリン・ポリペプチド及びその製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2005049650A1 JPWO2005049650A1 (ja) | 2007-10-04 |
JP4627263B2 true JP4627263B2 (ja) | 2011-02-09 |
Family
ID=34616820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005515538A Expired - Lifetime JP4627263B2 (ja) | 2004-02-16 | 2004-02-16 | ラクトフェリン・ポリペプチド及びその製造方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20070197426A1 (ja) |
JP (1) | JP4627263B2 (ja) |
WO (1) | WO2005049650A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2734543B1 (en) * | 2011-07-24 | 2018-10-03 | Carmel-Haifa University Economic Corp. | Lactoferrin fragments and use thereof |
EP2989120A4 (en) | 2013-04-25 | 2017-04-19 | Carmel-Haifa University Economic Corp. | Synthetic anti-inflammatory peptides and use thereof |
CN114129713B (zh) * | 2021-11-23 | 2024-05-24 | 南方科技大学 | 乳铁蛋白活性肽或编码该活性肽的核苷酸序列在制备抗炎和/或抗氧化产品中的应用 |
-
2004
- 2004-02-16 US US10/589,482 patent/US20070197426A1/en not_active Abandoned
- 2004-02-16 WO PCT/JP2004/001614 patent/WO2005049650A1/ja active Application Filing
- 2004-02-16 JP JP2005515538A patent/JP4627263B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPWO2005049650A1 (ja) | 2007-10-04 |
US20070197426A1 (en) | 2007-08-23 |
WO2005049650A1 (ja) | 2005-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ghebrehiwet et al. | cC1q-R (calreticulin) and gC1q-R/p33: ubiquitously expressed multi-ligand binding cellular proteins involved in inflammation and infection | |
JP3100005B2 (ja) | ヒト免疫不全ウィルス感染・増殖抑制剤 | |
TW464656B (en) | Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease | |
Parker et al. | Purification and characterization of a recombinant version of human α-fetoprotein expressed in the milk of transgenic goats | |
Tada et al. | Proteolysis of CD14 on human gingival fibroblasts by arginine-specific cysteine proteinases from Porphyromonas gingivalis leading to down-regulation of lipopolysaccharide-induced interleukin-8 production | |
US5639593A (en) | Method for determining TNF | |
US6084069A (en) | Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy | |
Pereira et al. | CAP37, a neutrophil granule‐derived protein stimulates protein kinase C activity in endothelial cells | |
JP3268777B2 (ja) | セリンプロテアーゼをコードするdna―配列とその関連対象物 | |
JP4627263B2 (ja) | ラクトフェリン・ポリペプチド及びその製造方法 | |
JP2011006468A (ja) | ラクトフェリン・ポリペプチド及びその製造方法 | |
JP3163171B2 (ja) | IgA産生促進剤 | |
EP1506233B1 (en) | Active complex of alpha-lactalbumin (hamlet) and cofactor | |
EP0499541A1 (fr) | Procédé de purification d'une protéine fortement glycosylée | |
JPS63173594A (ja) | 発癌遺伝子により誘導される分泌タンパク質 | |
JP2011503137A (ja) | 新規のアルギニン置換ペプチド及びその使用 | |
Sarfati et al. | T-cell-derived IgE-binding factors. II. Purification and characterization of IgE-binding factors produced by human T cell leukemia/lymphoma virus-1-transformed T lymphocytes. | |
MacKAY et al. | Quantitative recovery, selective removal and one‐step purification of human parotid and leukemic lysozymes by immunoadsorption | |
JP5312025B2 (ja) | Il−32モジュレーター | |
JP4476934B2 (ja) | 新規ペプチドおよび免疫賦活剤、機能性食品ならびに機能性食品の製造方法 | |
JP2006514699A (ja) | 肝疾患に対するccケモカイン変異体の使用 | |
Hayashi et al. | Reduction of Serum Interferon (IFN)-γ Concentration and Lupus Development in NZBxNZWF1Mice by Lactic Dehydrogenase Virus Infection | |
JP2001501818A (ja) | 細胞を培養する方法 | |
Coyne et al. | A mechanism of TNFR type II (75 kDa)“shedding” in macrophages | |
Chen et al. | Complement C5a/C5aR pathways enhance macrophage apoptosis via activation of caspase-3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A5211 Effective date: 20050215 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20050216 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050215 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20060616 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060719 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060919 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20061018 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061218 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070201 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20070302 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20091201 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20091201 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100405 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100906 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101104 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131119 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4627263 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |